האיחוד האירופי - גרמנית - EMA (European Medicines Agency)

sanofi winthrop industrie - teriflunomide - multiple sklerose - selektive immunsuppressiva - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

האיחוד האירופי - גרמנית - EMA (European Medicines Agency)

menarini international operations luxembourg s.a. - pemetrexeddinatriumhemipentahydrat - carcinoma, non-small-cell lung; mesothelioma - antineoplastische mittel - malignant pleural mesothelioma ciambra in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancer ciambra in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. ciambra ist indiziert als monotherapie für die wartung behandlung von lokal fortgeschrittenem oder metastasierendem nicht-kleinzelligem lungenkrebs anderen als überwiegend plattenepithel-histologie bei patienten, deren krankheit nicht fortgeschritten ist sofort nach der platin-basierten chemotherapie. ciambra ist indiziert als monotherapie für die zweitlinientherapie von patienten mit lokal fortgeschrittenem oder metastasiertem nicht-kleinzelligem lungenkrebs andere als plattenepithelkarzinom klassifiziert ist.

האיחוד האירופי - גרמנית - EMA (European Medicines Agency)

medimmune llc - reassortanten-influenzavirus (lebend-attenuiert) der folgenden stämme:a/california/7/2009 (h1n1)pdm09-ähnlicher stamm, a/victoria/361/2011 (h3n2) - ähnlicher stamm b/massachusetts/2/2012-ähnlicher stamm - influenza, human; immunization - impfstoffe - prophylaxe der influenza bei personen 24 monate bis unter 18 jahren. die anwendung von fluenz sollte auf offiziellen empfehlungen.

האיחוד האירופי - גרמנית - EMA (European Medicines Agency)

astrazeneca ab - a/darwin/9/2021 (h3n2) - like strain (a/norway/16606/2021, medi 355293) / a/victoria/2570/2019 (h1n1)pdm09 - like strain (a/victoria/1/2020, medi 340505) / b/austria/1359417/2021 - like strain (b/austria/1359417/2021, medi 355292) / b/phuket/3073/2013 - like strain (b/phuket/3073/2013, medi 306444) - influenza, mensch - influenza-impfstoffe, influenza, lebend-attenuiert - prophylaxis of influenza in children and adolescents from 24 months to less than 18 years of age. die anwendung von fluenz tetra sollte auf offiziellen empfehlungen basieren.

האיחוד האירופי - גרמנית - EMA (European Medicines Agency)

merial - lebend abgeschwächten muscovy-duck-parvovirus - immunologischen arzneimitteln für aves, ente, parvovirus, live virale impfstoffe - enten - aktive immunisierung von enten zur verhinderung von mortalität1 und zur verringerung von gewichtsverlust und läsionen von entenparvovirose und derzsy-krankheit. 1 in abwesenheit von maternal abgeleiteten antikörpern.

האיחוד האירופי - גרמנית - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - immunologischen arzneimitteln für felidae, - katzen - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs. onsets of immunity isone week after primary vaccination course. the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.

האיחוד האירופי - גרמנית - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline panleucopenia virus (pli iv) - immunologischen arzneimitteln für felidae, - katzen - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs. onset of immunity is one week after primary vaccination course the duration of immunity is one year after the primary vaccination course and three years after the last re-vaccination.

האיחוד האירופי - גרמנית - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologischen arzneimitteln für felidae, - katzen - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

האיחוד האירופי - גרמנית - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunologischen arzneimitteln für felidae, - katzen - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. anfänge der immunität wurden eine woche nach der grundimmunisierung für rhinotracheitis, calicivirus, chlamydophila felis und panleukopenie nachgewiesen. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

אוסטריה - גרמנית - AGES (Agentur für Gesundheit und Ernährungssicherheit)

accord healthcare b.v. - vinorelbintartrat -